Accuray Incorporated (ARAY) News
Filter ARAY News Items
ARAY News Results
|Loading, please wait...|
ARAY News Highlights
- For ARAY, its 30 day story count is now at 18.
- Over the past 19 days, the trend for ARAY's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- The most mentioned tickers in articles about ARAY are LUNG, DECK and TT.
Latest ARAY News From Around the Web
Below are the latest news stories about Accuray Inc that investors may wish to consider to help them evaluate ARAY as an investment opportunity.
Largest Hospital in Queensland, Australia Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies
Accuray Incorporated (NASDAQ: ARAY) announced today that Royal Brisbane and Women's Hospital (RBWH), the largest medical facility in Queensland, Australia, has selected two Radixact Systems with ClearRT™ helical fan-beam kVCT imaging and Synchrony® artificial intelligence (AI)-driven four-dimensional (4D) dynamic delivery technology to expand access to potentially life-saving radiotherapy treatments to more patients. The Radixact Systems will replace existing, older TomoTherapy® Systems and in c
Accuray (ARAY) said data from a phase 3 trial, dubbed TomoBreast, suggested that post-surgery hypofractionated radiotherapy delivered with the TomoTherapy System is superior to…
Accuray Incorporated (NASDAQ: ARAY) announced data from a Phase 3 TomoBreast trial of TomoTherapy System (TT) versus conventional post-surgery radiotherapy (CR) for breast cancer designed to test the hypothesis that TT might reduce lung-heart toxicity. An analysis of patient-reported outcomes showed 10-year survival free of heart and lung deterioration was 84.5% with TomoTherapy delivered radiotherapy, a significant improvement above the 66.9% achieved with conventional radiotherapy. The TomoThe
Accuray TomoTherapy® Helical Radiotherapy System Helps Preserve Breast Cancer Patients' Long-term Heart and Lung Functionality
Accuray Incorporated (NASDAQ: ARAY) announced today that data from a phase III, randomized controlled trial, TomoBreast, indicate post-surgery hypofractionated radiotherapy delivered with the TomoTherapy® System is superior to conventional radiotherapy in preserving long-term heart and lung functioning in women with early breast cancer. An analysis of patient reported outcomes showed 10-year survival free of heart and lung deterioration was 84.5% with TomoTherapy delivered radiotherapy - a signi
Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 15-17, 2022. As part of the conference, the company's management team will participate in a virtual fireside chat on Wednesday, February 16, 2022 at 3:30 pm EST / 12:30 pm PST.
Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...
Accuray Incorporated (ARAY) Q2 2022 Earnings Conference Call Jan 26, 2022 04:30 PM ET Company Participants Ken Mobeck - VP, Finance and IR Joshua Levine - President and CEO Suzanne Winter - President Brandon Green - Interim CFO Conference Call Participants Michael Cox - Lake Street Capital Markets Marie Thibault...
Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.
ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022
Welcome to Accuray's conference call to review financial results for the second quarter of fiscal year 2022, which ended December 31, 2021. Joining us on today's call are Josh Levine, Accuray's chief executive officer; Suzanne Winter, Accuray's president; and Brandy Green, Accuray's interim chief financial officer.